This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okazaki, R. Articles by Takeuchi, Y. Search for Related Content PubMed PubMed Citation Articles by Okazaki, R. Articles by Takeuchi, Y.

Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro¹

Third Department of Medicine, Teikyo University School of Medicine (R.O., M.T., K.T.), Ichihara, Chiba 299-0111; the Division of Endocrinology, Department of Internal Medicine, University of Tokyo School of Medicine (S.F., T.F., Y.T.), Bunkyo-ku, Tokyo 112-8688; and Sankyo Co., Ltd., Pharmacology and Molecular Biology Research Laboratories (M.M.), Shinagawa-ku, Tokyo 140-8710, Japan

Address all correspondence and requests for reprints to: Ryo Okazaki, M.D., Third Department of Medicine, Teikyo University School of Medicine, 3426–3 Anesaki, Ichihara, 299-0111 Japan. E-mail: rokazaki{at}med.teikyo-u.ac.jp

Osteoblasts and adipocytes are derived from common bone marrow stromal cells that play crucial roles in the generation of osteoclasts. Activation of peroxisome proliferator-activated receptor- (PPAR) induces adipogenic differentiation of stromal cells; however, whether this would affect osteoblast/osteoclast differentiation is unknown. Thus, we examined the effects of the thiazolidinedione (TZD) class of antidiabetic agents that activate PPAR on osteoblast/osteoclast differentiation using mouse whole bone marrow cell culture. As reported, all TZDs we tested (troglitazone, pioglitazone, and BRL 49653) markedly increased the number of Oil Red O-positive adipocytes and the expression of adipsin and PPAR 2. 1,25-Dihydroxyvitamin D₃ [1,25-(OH)₂D₃] did not affect adipogenic differentiation induced by TZDs. TZDs did not affect alkaline phosphatase activity, an early marker of osteoblastic differentiation, despite their marked adipogenic effects. TZDs decreased the number of tartrate-resistant acid phosphatase-positive multinucleated osteoclast-like cells induced by 1,25-(OH)₂D₃ or PTH. Troglitazone dose dependently inhibited basal and 1,25-(OH)₂D₃- and PTH-induced bone resorption as assessed by pit formation assay. Interleukin-11 blocked the induction by troglitazone of adipogenesis, but had no effect on the inhibition of osteoclast-like cell formation. These results indicate that TZDs are potent inhibitors of bone resorption in vitro. Inhibitory effects of TZDs on osteoclastic bone resorption was not osteotropic factor specific and did not appear to be related to their adipogenic effects. Thus, TZDs may suppress bone resorption in diabetic patients and prevent bone loss.

This article has been cited by other articles:

				Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. Bascil Tutuncu, and N. Guvener Demirag Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3523 - 3530. [Abstract] [Full Text] [PDF]

				O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J. Suva, and B. Lecka-Czernik Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone Endocrinology, June 1, 2007; 148(6): 2669 - 2680. [Abstract] [Full Text] [PDF]

				A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, J. Davidson, and I. R. Reid The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1305 - 1310. [Abstract] [Full Text] [PDF]

				D. G. Haider, F. Mittermayer, G. Schaller, M. Artwohl, S. M. Baumgartner-Parzer, G. Prager, M. Roden, and M. Wolzt Free fatty acids normalize a rosiglitazone-induced visfatin release Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E885 - E890. [Abstract] [Full Text] [PDF]

				A. M. Schwab, S. Granholm, E. Persson, B. Wilkes, U. H. Lerner, and H. H. Conaway Stimulation of Resorption in Cultured Mouse Calvarial Bones by Thiazolidinediones Endocrinology, October 1, 2005; 146(10): 4349 - 4361. [Abstract] [Full Text] [PDF]

				V. Gaillard, D. Casellas, C. Seguin-Devaux, H. Schohn, M. Dauca, J. Atkinson, and I. Lartaud Pioglitazone Improves Aortic Wall Elasticity in a Rat Model of Elastocalcinotic Arteriosclerosis Hypertension, August 1, 2005; 46(2): 372 - 379. [Abstract] [Full Text] [PDF]

				A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation Endocrinology, March 1, 2005; 146(3): 1226 - 1235. [Abstract] [Full Text] [PDF]

				M A. Soroceanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J. Endocrinol., October 1, 2004; 183(1): 203 - 216. [Abstract] [Full Text] [PDF]

				M. Zayzafoon, W. E. Gathings, and J. M. McDonald Modeled Microgravity Inhibits Osteogenic Differentiation of Human Mesenchymal Stem Cells and Increases Adipogenesis Endocrinology, May 1, 2004; 145(5): 2421 - 2432. [Abstract] [Full Text] [PDF]

				A. Meirhaeghe, L. Fajas, F. Gouilleux, D. Cottel, N. Helbecque, J. Auwerx, and P. Amouyel A Functional Polymorphism in a STAT5B Site of the Human PPAR{gamma}3 Gene Promoter Affects Height and Lipid Metabolism in a French Population Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 289 - 294. [Abstract] [Full Text] [PDF]

				Y. Takeuchi, S. Watanabe, G. Ishii, S. Takeda, K. Nakayama, S. Fukumoto, Y. Kaneta, D. Inoue, T. Matsumoto, K. Harigaya, et al. Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice J. Biol. Chem., December 6, 2002; 277(50): 49011 - 49018. [Abstract] [Full Text] [PDF]

				J D Tugwood and C T Montague Biology and toxicology of PPARg ligands Human and Experimental Toxicology, August 1, 2002; 21(8): 429 - 437. [Abstract] [PDF]

				R. Okazaki, D. Inoue, M. Shibata, M. Saika, S. Kido, H. Ooka, H. Tomiyama, Y. Sakamoto, and T. Matsumoto Estrogen Promotes Early Osteoblast Differentiation and Inhibits Adipocyte Differentiation in Mouse Bone Marrow Stromal Cell Lines that Express Estrogen Receptor (ER) {alpha} or {beta} Endocrinology, June 1, 2002; 143(6): 2349 - 2356. [Abstract] [Full Text] [PDF]

				L. L. Demer Adipose Rex: Fat and Fats That Rule Differentiation Circ. Res., February 22, 2002; 90(3): 241 - 243. [Full Text] [PDF]

				J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz Changes in Proinflammatory Cytokine Activity after Menopause Endocr. Rev., February 1, 2002; 23(1): 90 - 119. [Abstract] [Full Text] [PDF]

				A. C. Bendixen, N. K. Shevde, K. M. Dienger, T. M. Willson, C. D. Funk, and J. W. Pike IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1 PNAS, February 15, 2001; (2001) 41493198. [Abstract] [Full Text]

				A. C. Bendixen, N. K. Shevde, K. M. Dienger, T. M. Willson, C. D. Funk, and J. W. Pike IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1 PNAS, February 27, 2001; 98(5): 2443 - 2448. [Abstract] [Full Text] [PDF]